Greater awareness of biosimilars and shared decision-making among patients attending rheumatology practices in Colorado,United States:Real-world data  

作　　者：Rovshan Ismailov Steven Simoens Zaytuna Khasanova 

机构地区：[1]Complex Mechanisms of Disease,Aging and Trauma Research Foundation,Denver,CO 80246,United States [2]Department of Pharmaceutical and Pharmacological Sciences,KU Leuven,Leuven 3000,Belgium

出　　处：《World Journal of Rheumatology》2020年第1期1-10,共10页世界风湿病学杂志

摘　　要：BACKGROUND There is a lack of studies and educational programs focused on biosimilars and shared decision-making among patients diagnosed with various rheumatic diseases.AIM To improve knowledge and awareness of biosimilars and shared decision-making among patients attending rheumatology practices in Colorado as well as to assess a rheumatology patient’s interest in discussing biosimilars as well as shared decision-making with others(e.g.,medical professionals,family members,friends).METHODS Our goal was to work with 80 rheumatology teams in Colorado.We developed and distributed 2000 multi-page brochures to each participating office and later conducted an online anonymous survey.RESULTS There were a total of 49(2.5%)rheumatology patients who responded to our survey.After reading our educational booklet,many survey respondents identified the correct answer in most questions focused on biosimilars or shared decision-making.Our survey results suggest that patients attending rheumatology practices in Colorado are generally not involved in discussions with their providers regarding treatment plans or options.The improvement in scores after reading our educational materials was statistically significant for biosimilars and shared decision-making.CONCLUSION Overall,the level of knowledge and awareness of biosimilars and shared decisionmaking among patients attending rheumatology practices in Colorado was low.More educational programs as well as follow up trainings to measure changes in knowledge and awareness regarding biosimilars and shared decision-making among patients attending rheumatology practices are recommended.

关 键 词：PATIENTS BIOSIMILARS Shared decision-making Education Survey AWARENESS 

分 类 号：R73[医药卫生—肿瘤]